ViewRay

ViewRay Inventory/Revenue

The Inventory to Revenue Ratio of ViewRay (VRAYQ) as of Oct 22, 2026 is 30.63 %. In the previous year, Inventory to Revenue Ratio was 42.24 % — a change of -27.49% (lower).

Inventory/Revenue

30.63 %

YoY

-27.49%

Last updated:

Inventory to Revenue Ratio of ViewRay is 2022 30.63 % . Inventory to Revenue Ratio of ViewRay was 2021 42.24 % . It decreases by -27.49% lower compared to the previous year.

The ViewRay Inventory/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory/Revenue
Date
Inventory/Revenue
Jan 1, 2015
77.70 USD
Jan 1, 2016
36.34 USD
Jan 1, 2017
56.91 USD
Jan 1, 2018
61.09 USD
Jan 1, 2019
62.69 USD
Jan 1, 2020
81.80 USD
Jan 1, 2021
42.24 USD
Jan 1, 2022
30.63 USD
The ViewRay Inventory/Revenue history
YEARInventory/RevenueYoY
30.63 %-27.49%
42.24 %-48.37%
81.80 %+30.49%
62.69 %+2.62%
61.09 %+7.34%
56.91 %+56.60%
36.34 %-53.22%
77.70 %+197,154.32%
0.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViewRay Stock analysis

What does ViewRay do? ViewRay Inc. is an American medical technology company based in Cleveland, Ohio. It was founded in 2004 by Ivor Jankovic and specializes in the manufacturing of radiation therapy devices. The history of ViewRay begins with the idea of developing innovative technology to treat cancer patients more effectively and gently. In 2005, the company entered into an agreement with the Cleveland Clinic Lerner Research Institute to conduct research on a novel magnetic resonance-guided radiation therapy machine. The research project was led by James F. Dempsey, Chair of the Department of Radiation Oncology at the Cleveland Clinic. In 2009, the first magnetic resonance-guided radiation therapy system was delivered and implemented at the Cleveland Clinic. ViewRay's business model is based on the development and manufacturing of innovative medical devices aimed at making the treatment of cancer patients more effective and gentle. The company focuses on combining magnetic resonance imaging (MRI) and radiation therapy to ensure more precise and safer treatment. ViewRay offers various products, including the MRIdian-Linac system, an advanced radiation therapy device that utilizes MRI technology to provide real-time images of the tumor during radiation. This allows for precise targeting of the tumor while sparing the surrounding tissue. The system also offers the ability to sync radiation therapy with the patient's breathing cycle, further improving the accuracy and effectiveness of the treatment. In addition to the MRIdian-Linac system, ViewRay also offers the MRIdian-MRI system, which is solely dedicated to imaging. The MRIdian-MRI is a diagnostic instrument that allows for better visualization of tissue and tumor studies. The system uses the same MRI technology as the MRIdian-Linac to generate radiation-free images. ViewRay has also specialized in the development of software tools that assist doctors in better planning and monitoring radiation therapy. This includes the RayCare Oncology Information System, which provides a comprehensive workflow and management platform, as well as the RayStation Treatment Planning Software, which enables more precise radiation therapy planning. In terms of market reach, ViewRay has a global presence. The company has a strong presence in North America, Europe, and Asia, and works closely with leading research institutes and hospitals to evaluate and improve the effectiveness and efficiency of its technologies. Overall, ViewRay has developed an innovative and unique portfolio of products and solutions that improve radiation therapy and increase accuracy and safety for patients and doctors. The company is a leader in the development of MRI-guided radiation therapy systems and is expected to continue playing a significant role in the medical technology industry in the future. ViewRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViewRay stock

Inventory to Revenue Ratio of ViewRay is 30.63 % in 2022.

Inventory to Revenue Ratio of ViewRay changed from 42.24 % to 30.63 %, representing a -27.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory to Revenue Ratio ViewRay since 2006 – with annual values, charts, and detailed analysis.

The Inventory/Revenue ratio shows what percentage of revenue is held as inventory. Rising ratios may indicate slowing demand or inventory management issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory to Revenue Ratio's ViewRay with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ViewRay

All Key Metrics — ViewRay